Tuberous sclerosis complex (TSC), an autosomal dominant disease caused by mutations in either TSC1 or TSC2, is characterized by the development of hamartomas in a variety of organs. Concordant with the tumour-suppressor model, loss of heterozygosity (LOH) is known to occur in these hamartomas at both TSC1 and TSC2 loci. LOH has been documented in renal angiomyolipomas, but loss of the wild-type allele in cortical tubers appears very uncommon. We analysed 24 hamartomas from 10 patients for second-hit mutations by several methods, and found no evidence for the inactivation of the second allele in many of the central nervous system (CNS) lesions, including tumours that appear to be clonally derived. We believe that somatic mutations in TSC1 and TSC2 resulting in the loss of wild-type alleles may not be necessary in some tumour types, and other mechanisms may contribute to tumorigenesis in this setting. We have shown that hamartin interacts with neurofilament light chain (NF-L) and could integrate the neuronal cytoskeleton through its direct interaction with NF-L and ERM (ezrin/radixin/moeisin) proteins. Our unpublished work further documents the binding of tuberin with Pam, a protein associated with c-Myc, which is enriched in brain. All these observations suggest that the tuberin-hamartin complex is likely to have distinct functions in the CNS.
Introduction
Tuberous sclerosis complex (TSC), an autosomal dominant disease caused by mutations in either TSC1 or TSC2 [1, 2] , is characterized by seizures, mental retardation and multiple hamartomas in many organs. Major TSC lesions include cortical tubers, subependymal nodules and subependymal giant cell astrocytomas (SEGAs) in the brain, multiple retinal nodular hamartomas, hypomelanotic macules, facial angiofibromas, shagreen patches and periungual fibromas of the skin, cardiac rhabdomyomas, renal angiomyolipomas (AMLs) and pulmonary lymphangioleiomyomatosis.
Loss of heterozygosity (LOH) of both TSC1 and TSC2, has been documented in TSC hamartomas, supporting the classification of the TSC genes as tumour-suppressor genes [3] [4] [5] [6] [7] . However, LOH frequencies vary significantly among tumour types. Renal AMLs reveal a high frequency of LOH, while central nervous system (CNS) lesions show a low frequency of LOH [5] . Similarly, renal cellular carcinomas in the Eker rat, a naturally occurring model in which the homologous Tsc2 gene is mutated, show a higher frequency of LOH compared with other tumours in these animals [8] [9] [10] . Tsc2 +/− mice also display a variable frequency of LOH in their tumours [11] .
Survey of somatic mutations in TSC lesions
Although LOH studies have been accomplished in a variety of TSC hamartomas by several investigators, a systematic study of somatic mutations in TSC lesions has not been reported. A previous study performed on renal AMLs, cortical tubers and facial angiofibromas from TSC patients with known germline mutations in TSC2 showed LOH in a majority of the AMLs and an intragenic deletion spanning 22-25 kb in two of the three angiofibromas, thus documenting the complete inactivation of the TSC2 gene [12] . This study, however, failed to detect the somatic mutations in cortical tubers. Failure to demonstrate the somatic events in TSC hamartomas have been attributed to either subtle variations in the TSC genes or to a mixture of normal and abnormal cells in the lesions [12, 13] . We therefore undertook a detailed analysis of the somatic mutations in 24 hamartomas obtained from 10 different patients with TSC for whom germline TSC1/TSC2 mutations were determined. Patient 9 is an autopsy case with multiple-organ involvement, and we obtained five tuber samples in addition to two AMLs and two SEGAs from this patient. Our results clearly support the idea that complete inactivation of the TSC genes following the classic Knudson model, requiring a second somatic mutation in the wild-type allele, is characteristic of renal AMLs, but not other TSC lesions, particularly cortical tubers [14] . Laser-capture microdissection performed on one of the AML samples further showed that blood vessel, smooth muscle and adipose tissue all harbour the same second somatic mutation.
In many of the tumours analysed, no mutation other than the germline mutation was detected by single strand conformation polymorphism (SSCP) screening. Since enough DNA was available for tuber samples 1, 4 and 5 obtained from patient 9, these samples were subjected to denaturing HPLC (DHPLC) analysis to look for subtle mutations that might have been missed by initial SSCP analysis. DHPLC also failed to detect a somatic event in these tubers, although the germline mutation was confirmed. Our attempts to detect other intragenic deletions by Southern blot and long-range PCR analyses in the tumours with sufficient DNA also failed to detect any variations. Hyper-methylation of the wild-type alleles leading to epigenetic gene silencing was considered, and no evidence of methylation of the TSC2 promoter region was noted. In order to determine the mRNA expression level of the wild-type allele, reverse transcriptase-PCR (RT-PCR) analysis was performed for the region spanning the germline mutation (1 bp deletion in TSC2 exon 33) in tubers 1, 4 and 5 of patient 9, as well as normal grey and white matter obtained from this patient. In all three tubers, the ratio of intensity of the wild-type to mutant alleles was similar to the ratio obtained from the normal brain samples ( Figure 1A ). Furthermore, laser-capture microdissection was carried out on tuber 5 from this patient, and balloon cells within the tubers were isolated. As controls, neurons and white matter were also dissected from the histologically normal cortex of this patient. These cells were subjected to LOH analysis using Kg8 and the 1 bp deletion in TSC2 exon 33 as markers. Balloon cells did not reveal LOH for these markers when compared with either normal spleen or the microdissected neurons and white matter ( Figure 1B ).
The lack of somatic mutations in some of the TSC lesions could also reflect a mixture of normal and abnormal cells in these lesions. We therefore carried out clonality analysis by PCR amplification of the highly polymorphic human androgen receptor gene ('HUMARA') in female patients. Five of the eight female patients were informative for this marker. Interestingly, many of the AML samples analysed were clonal. Of the three AMLs analysed from patient 10, only one was clonal, although all three tumours displayed LOH for TSC2. In patient 9, DNA from several hamartomas was tested for clonality along with normal tissues such as spleen and muscle. The hamartoma tissues analysed from this patient, however, revealed varied clonality. Of the two AMLs, AML1 was monoclonal in origin while AML2 was polyclonal. Among the five tubers analysed, tuber 1 (T1) was clonal, tubers 2-4 (T2-T4) were polyclonal and tuber 5 (T5) was skewed towards clonality. Similarly, one of the SEGAs (S1) revealed a skewed pattern and the second SEGA (S2) was polyclonal [14] .
The inability to identify a second, somatic event in either TSC1 or TSC2 in many tumour samples raises a number of different possibilities. For instance, trans-heterozygous mutations could occur as shown in autosomal dominant polycystic kidney disease with inactivation of one allele at each of the polycystic kidney disease PKD1 and PKD2 loci [1, 2] . We screened all tumour samples for somatic events in both TSC1 and TSC2 and found no evidence for a transheterozygous event. However, concurrent mutations in other gene(s) remain a possibility. Another potential mechanism for inactivation of the wild-type allele is somatic methylation, which is increasingly implicated in the pathogenesis of human cancer [15] . One study reports hyper-methylation of the von Hippel-Lindau gene in 33% of tumours, which do not display LOH [16] . We examined this possibility and found no evidence of methylation within TSC2 exon 1a near a defined promoter element. It is generally believed that many of the lesions seen in TSC are of mixed cell type, and a true tumour cell population could be low in abundance, resulting in a failure to detect the somatic events by LOH analysis. To address this we carried out clonality analysis, which revealed that some of the lesions that showed absence of a somatic mutation were indeed polyclonal. Among the lesions of patient 9, tuber 1 (T1) and the ungual fibroma were clearly clonal, while tuber 5 (T5) and one SEGA contained a relatively higher proportion of clonal cells, and the possibility of detecting the somatic events would be predicted. RT-PCR performed on the tubers showed equal expression of both alleles. In addition, the balloon cells microdissected from one of the tubers also failed to reveal loss of the other allele. Thus while lack of detection of a somatic mutation event in tumours that are polyclonal could be due to an admixture of normal cells, this cannot provide an explanation in tumours that are clonally derived.
Our study, as well as other reports, shows that a majority of AMLs seen in TSC is associated with loss of the wildtype allele, primarily as LOH. It has been suggested that tumorigenesis for brain lesions probably does not require the extensive LOH seen in AMLs and could be associated with subtle variations in the TSC genes [12] . We have carefully examined and found no evidence for subtle variations of the TSC genes in many of the lesions, particularly brain lesions. It is therefore possible that a second somatic mutation may not be strictly necessary for all cell types involved in TSC lesions. Immunohistochemistry studies performed for tuberin and hamartin in brain lesions report positive immunoreactivity for tuberin and hamartin in dysmorphic neurons of cortical tubers ( [17, 18] , and A. Puga, A. Stemmer-Rachamimov, and V. Ramesh, unpublished work), further supporting the idea that the TSC proteins are not completely lost in these lesions. These observations combined suggest the possibility that haplo-insufficiency of TSC1 and TSC2 genes may be sufficient for TSC lesion development in the CNS. Haploid levels of tuberin and hamartin may be inadequate to suppress the activity of downstream target proteins such as mammalian target of rapamycin ('mTOR'), which has been shown to play a role in the growth of TSC-associated lesions. Examining the status of phospho-p70 S6 kinase and mammalian target of rapamycin in TSC-derived CNS lesions is essential and these studies are currently underway in our laboratory.
Hamartin interacts with neurofilament light chain (NF-L) and possibly functions as a novel integrator of neuronal cytoskeleton
Based on studies from several laboratories, it has become evident that hamartin and tuberin associate with each other forming a tight complex. We have observed that hamartin binds the neurofilament light chain, and it is possible to recover the hamartin-tuberin complex over the neurofilament light-chain rod domain spanning amino acids 93-156 by affinity precipitation. Co-immunoprecipitations performed in rat brain further confirms their interaction in vivo (Figure 2 ). Homologous rod domains in other intermediate filaments such as neurofilament medium chain, α-internexin, vimentin and desmin are not able to bind hamartin. Therefore, hamartin association with intermediate filaments is probably restricted to neurons and is specific to NF-L [19] .
Co-localization of hamartin and tuberin with NF-L is enriched particularly in the proximal and central regions of neuronal growth cones, implicating this as a potential site of interaction for these proteins. An earlier study found hamartin to be associated with the ERM (ezrin/radixin/moeisin) family of actin-binding proteins in vitro and in vivo in human umbilical vein endothelial cells (HUVECs), and this interaction was shown to be required for activation of Rho by serum or lysophosphatidic acid [20] . We have confirmed that hamartin interacts with moesin, and in cultured primary neurons hamartin and tuberin reveal strong co-localization with ERMs in the distal region of growth cones (Figure 3 ) [19] . Interestingly, among the ERM family members, only radixin and moesin are concentrated in neuronal growth cones, and ezrin is restricted mainly to the cell body [21, 22] . Moesin and radixin have been clearly shown to regulate key aspects of growth-cone development and maintenance modulating neurite formation and polarity [21] [22] [23] . In neurons expressing reduced levels of radixin and moesin, growth-cone alterations are accompanied by a dramatic disorganization of F-actin [22] . It is likely that the association of the hamartin-tuberin complex with ERM proteins is essential for growth-cone maintenance and motility.
The ERM proteins are highly regulated, actin-binding proteins and have emerged as key molecules in linking F-actin to specific membrane proteins, especially in cellsurface structures [24] . The interaction of hamartin with ERM Figure 3 Co-localization of hamartin and the ERM proteins in the neuronal growth cone Hamartin was detected using anti-hamartin polyclonal antibody HF6-and Alexa488-conjugated anti-rabbit secondary antibody (A); ERM proteins were detected using 13H9, a mouse monoclonal antibody that detects all three protein family members, and Cy3-labelled secondary antibody (B). Overlapping images reveal co-localization of hamartin and ERMs in the central to distal part of the growth cone (C). Strong staining of ERM proteins was seen in the actin-rich peripheral zone. A compilation of all slices (n = 5) is shown in (D). Scale bar, 20 µm.
proteins is reported to be required upstream of Rho for lysophosphatidic acid-induced assembly of focal adhesions and actin-stress fibres [20] . Our results documenting the interaction of hamartin with NF-L imply that hamartin could function as a novel integrator of the neuronal cytoskeleton. It is possible that the association of hamartin with NF-L and ERM proteins might play an essential role in neuronal migration, and that abolishing this interaction by mutations in the TSC genes could explain certain neuronal differentiation and migration defects observed in TSC brains.
